Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Liposarcoma × Adjuvants, Pharmaceutic × Sarcoma × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma 1 Rhabdomyosarcoma 1 Recurrence 1 Osteosarcoma 1 Neuroblastoma 1 Neoplasms 1 Liposarcoma 1

Interventions

Doxorubicin 22 Radiotherapy 12 Ifosfamide 11 Trabectedin 10 pazopanib 5 Gemcitabine 5 ribociclib 4 pembrolizumab 4 Specimen Handling 4 Docetaxel 4 Biopsy 4 selinexor 3 palbociclib 3 eribulin 3 X-Rays 3 Imatinib Mesylate 3 Filgrastim 3 Cyclophosphamide 3 temsirolimus 2 romidepsin 2 pegfilgrastim 2 liposomal doxorubicin 2 cixutumumab 2 brostallicin 2 brigimadlin 2 belinostat 2 avelumab 2 abemaciclib 2 Vincristine 2 Temozolomide 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06116578 2025-12-01

NeoSarc

Gustave Roussy, Cancer Campus, Grand Paris

Phase 2 Withdrawn

Liposarcoma, Neoplasms, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡